|
Pharmacy and Therapeutics Committee
The Idaho Medicaid Pharmacy and Therapeutics Committee (P&T Committee) is comprised of Idaho health practitioners – physicians, physician assistant, pharmacists – who are committed to providing the right care at the right price. This committee meets four times per year to review clinical evidence. The P&T Committee makes recommendations to the Department of Health and Welfare regarding drug safety and efficacy as well as prior authorization requirements. Cost modeling analysis is done by the department twice per year – following the committee meetings in May and November.
Preferred Drug List (PDL)
General P&T Information
2019 Meeting Dates:
- April 18, 2019
- May 17, 2019
- October 18, 2019
- November 15, 2019
Members
Voting Members
- Andrei Rudyi, PharmD (Boise, serving since 2016)
- Brian Crownover, M.D. (Meridian, serving since 2015)
- Christopher Streeter, M.D. (Boise, serving since 2014)
- David Calley, PharmD (Meridian, serving since 2018)
- Jeffery Johnson, PharmD, PA (Eagle, serving since 2017)
- Joseph Weatherly, D.O. (Idaho Falls, serving since 2017
- Perry Brown, M.D. (Boise, serving since 2009)
- Paul Driver, PharmD (Lewiston, serving since 2016)
Non-Voting Members
- Mark Randleman, D.O. (Interim Medical Director)
- Tamara Eide, PharmD (Medicaid Pharmacy Supervisor)
- Alex Adams, PharmD, MPH (Executive director, Idaho Board of Pharmacy)
P&T Drug Review Schedule for 2018
Black = Magellan/Provider Synergies
Bold/Italicized = DERP Review
|
P&T Meeting Dates
|
New Reviews |
Re-Reviews
|
|
April 20, 2018 *
|
|
Angiotensin Modulators
Angiotensin Modulator Combinations
Antihypertensives, Sympatholytic
Beta Blockers
Calcium Channel Blockers
PAH Agents, Oral and Inhaled
Vasodilators, Coronary
Anticoagulants
Platelet Aggregation Inhibitors
Lipotropics, Other
Lipotropics, Statins
Androgenic Agents
BPH Treatments
Bladder Relaxant Preparations
Bone Resorption Suppression and Related Agents
Phosphate Binders
Growth Hormone
Cystic Fibrosis, Oral
Pancreatic Enzymes
Proton Pump Inhibitors
H. Pylori Treatments
GI Motility, Chronic
Ulcerative Colitis Agents
Hepatitis C Agents (Interferons and Ribavirin only)
|
|
May 18, 2018**
|
|
Hypoglycemics, Metformins
Hypoglycemics, Incretin Mimetics/Enhancers
Hypoglycemics, Insulin
Hypoglycemics, SGLT2
Hypoglycemics, TZD
Hereditary Angioedema Agents
Antivirals, Oral
Antivirals, Topical
Antibiotics, Inhaled
Antibiotics, Topical
Antibiotics, Vaginal
Cephalosporins and Related Agents
Fluroquinolones, Oral
Macrolides
Tetracyclines
Antibiotics, GI
Antifungals, Oral
Antifungals, Topical
Antiparasitics, Topical
Immunosuppressants, Oral
Multiple Sclerosis Agents
Antimigraine Agents, Triptans
Analgesics, Narcotic long-acting
Analgesics, Narcotic short-acting
Opiate Dependence
Skeletal Muscle Relaxants
Antiemetics/Antivertigo Agents
|
|
October 19,
2018 ***
|
|
Anti-Allergens, Oral
Antihistamines, Minimally Sedating
Intranasal Rhinitis
Epinephrine, Self-injected
Immunomodulators, Atopic Dermatitis
Immune Globulins
Immunomodulators, Asthma
Bronchodilators, Beta Agonist
Glucocorticoids, Inhaled
Leukotriene Modifiers
COPD Agents
Smoking Cessation
Cytokine/CAM Agents
Botulinum Toxins
Ophthalmic Antibiotics
Ophthalmic Antibiotic/Steroid Combinations
Ophthalmic Antiinflammatories, Immunomodulators
Ophthalmics for Allergic Conjunctivitis
|
|
November 16, 2018****
|
|
Otic Antibiotics
NSAIDs
Pain, Other
Antipsychotics, Atypical
Antipsychotics, Typical
Antidepressants, Other
Antidepressants, SSRIs
Anticonvulsants
Anxiolytics/Benzodiazepines
Stimulants and Related Agents
Sedative Hypnotics
Alzheimer’s Agents
Antiparkinsons Agents/Restless Leg Syndrome
Movement Disorders
Antihyperurecemics, Oral
Colony Stimulating Factors
Erythropoiesis Stimulating Proteins
|
*The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, May 21, 2018. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following the May meeting. These final decisions will be effective July 2, 2018.
**The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, May 21, 2018. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following this meeting. These final decisions will be effective July 2, 2018.
***The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, November 19, 2018. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following the November meeting. These final decisions will be effective January 2, 2019.
****The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, November 19, 2018. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following this meeting. These final decisions will be effective January 2, 2019.
|
|